我們已在上線！進一步了解

Jazz Pharmaceuticals

JAZZ

市值 US$136億

210.23 USD

-4.19

1.95%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

210.50

+0.27

0.13%

1天

-1.95%

5天

-3.96%

1個月

-13.7%

3個月

-13.19%

6個月

6.27%

今年迄今

21.41%

1年

56.6%

5年

49.78%

10年

78.63%

關於： Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

員工： 2,890

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 57.8%

中性 37.8%

負面 4.4%

Zacks Investment Research

Is JAZZ Stock Still a Smart Way to Play Medical Cannabis?

Jazz Pharmaceuticals offers a differentiated medical cannabis play, with Epidiolex sales growth and a diversified portfolio offset by pipeline setbacks and earnings pressures.

Is JAZZ Stock Still a Smart Way to Play Medical Cannabis?

Jazz Pharmaceuticals: Ziihera And Portfolio Diversification Are Changing The Earnings Story

Jazz Pharmaceuticals is transforming beyond oxybate reliance, with diversified growth across sleep medicine, epilepsy, and oncology portfolios. JAZZ delivered robust Q2 2026 results: $1.21B revenue (+16% YoY), strong gross margins (92.1% non-GAAP), and raised FY guidance to $4.60–$4.75B. Ziihera's FDA approval for 1L HER2-positive GEA marks a major oncology expansion, with clinical data showing a significant survival benefit over standard of care.

Jazz Pharmaceuticals: Ziihera And Portfolio Diversification Are Changing The Earnings Story

Zacks Investment Research

Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock

Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B

Jazz Pharmaceuticals NASDAQ: JAZZ executives outlined the company's oncology growth strategy, early commercial progress for recently launched therapies and business-development priorities during the Morgan Stanley Global Healthcare Conference.

Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B

Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands

Jazz Pharmaceuticals NASDAQ: JAZZ outlined development and commercial plans for its oncology, epilepsy and sleep franchises during a discussion with Deutsche Bank analyst David Hoang, emphasizing the expansion potential of HER2-targeted therapy Ziihera and ongoing lifecycle work for EPIDIOLEX. Get Jazz Pharmaceuticals alerts:Sign UpZiihera Data and Development Plans An unnamed Jazz executive said zanidatamab, marketed as Ziihera, produced a statistically significant overall-survival result for its zanidatamab-plus-chemotherapy arm versus a control arm in a second interim analysis.

Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands

The Motley Fool

Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition?

Jazz paid $820 million up front to acquire Actio Biosciences. Actio shareholders could receive another $500 million in milestone payments.

Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition?

Jazz Pharmaceuticals plc (JAZZ) Presents at Deutsche Bank 2026 Healthcare Summit Transcript

Jazz Pharmaceuticals plc (JAZZ) Presents at Deutsche Bank 2026 Healthcare Summit Transcript

Jazz Pharmaceuticals plc (JAZZ) Presents at Deutsche Bank 2026 Healthcare Summit Transcript

Jazz Pharmaceuticals plc (JAZZ) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Jazz Pharmaceuticals plc (JAZZ) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Jazz Pharmaceuticals plc (JAZZ) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Acquisition adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1-related epilepsy Transaction strengthens Jazz's epilepsy pipeline and reinforces its commitment to advance treatment options in rare disease DUBLIN, Sept. 15, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. ("Actio") for $820 million upfront.

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc (JAZZ) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Jazz Pharmaceuticals plc (JAZZ) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Jazz Pharmaceuticals plc (JAZZ) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

查看新聞排名

價格圖表採用Lightweight Charts™實作